Lower GI 2017

5. HDR-EBT – Definitive option

Herbert study (presented at ESTRO 2016) - Dose-finding feasibility study of EBRT + HDR-EBT boost for patients unfit for surgery - Rectal adenocarcinoma < 15 cm, < 2/3 of circumference, cT2-4 N0-1 M0-1 - Life expectancy ≥ 6 months

Marijnen C., Rijkmans E. LUMC, Leiden, The Netherlands. Presented at ESTRO 2016